[Form 4] Avita Medical, Inc. Insider Trading Activity
David O'Toole, identified as the Chief Financial Officer, filed a Form 4 reporting a change in beneficial ownership of Avita Medical, Inc. (RCEL). The filing shows he acquired 2,000 shares of common stock on 08/12/2025 at a price of $4.81 per share, increasing his direct holdings to 29,657 shares. The transaction is reported under transaction code P and the Form 4 was filed by one reporting person.
David O'Toole, identificato come Chief Financial Officer, ha depositato un Form 4 che segnala una variazione della titolarit脿 effettiva di Avita Medical, Inc. (RCEL). Il documento indica l'acquisto di 2,000 azioni ordinarie in data 08/12/2025 al prezzo di $4.81 per azione, portando la sua partecipazione diretta a 29,657 azioni. L'operazione 猫 segnalata con il codice di transazione P e il Form 4 猫 stato presentato da una sola persona dichiarante.
David O'Toole, identificado como Chief Financial Officer, present贸 un Form 4 informando un cambio en la titularidad de Avita Medical, Inc. (RCEL). El informe muestra que adquiri贸 2,000 acciones ordinarias el 08/12/2025 a un precio de $4.81 por acci贸n, incrementando su tenencia directa a 29,657 acciones. La transacci贸n se reporta con el c贸digo P y el Form 4 fue presentado por una sola persona informante.
David O'Toole鞚� 斓滉碃鞛毂呾瀯鞛�(CFO)搿� 頇曥澑霅橂┌, Avita Medical, Inc. (RCEL)鞐� 雽�頃� 鞁れ 靻岇湢甓� 氤�霃欖潉 氤搓碃頃橂姅 Form 4毳� 鞝滌稖頄堨姷雼堧嫟. 靹滊鞐� 霐半ゴ氅� 攴鸽姅 08/12/2025鞐� 氤错喌欤� 2,000欤茧ゼ 欤茧嫻 $4.81鞐� 旆摑頃橃棳 攴胳潣 歆侅为 氤挫湢霟夓澊 29,657欤茧 歃濌皜頄堨姷雼堧嫟. 瓯半灅電� 瓯半灅 旖旊摐 P搿� 氤搓碃霅橃棃瓿�, Form 4電� 頃� 氇呾潣 氤搓碃鞚胳澊 鞝滌稖頄堨姷雼堧嫟.
David O'Toole, identifi茅 comme Chief Financial Officer, a d茅pos茅 un Form 4 signalant un changement de d茅tention b茅n茅ficiaire de Avita Medical, Inc. (RCEL). Le d茅p么t indique qu'il a acquis 2,000 actions ordinaires le 08/12/2025 au prix de $4.81 par action, portant sa d茅tention directe 脿 29,657 actions. La transaction est d茅clar茅e sous le code P et le Form 4 a 茅t茅 d茅pos茅 par une seule personne d茅clarante.
David O'Toole, ausgewiesen als Chief Financial Officer, hat ein Form 4 eingereicht, das eine 脛nderung des wirtschaftlichen Eigentums an Avita Medical, Inc. (RCEL) meldet. Dem Eintrag zufolge erwarb er am 08/12/2025 2,000 Stammaktien zu je $4.81, wodurch seine direkten Best盲nde auf 29,657 Aktien stiegen. Die Transaktion ist mit dem Transaktionscode P gemeldet, und das Form 4 wurde von einer meldenden Person eingereicht.
- Reported acquisition: David O'Toole purchased 2,000 shares at $4.81, increasing direct holdings to 29,657.
- Clear disclosure: Form 4 identifies the reporting person as CFO and was filed by one reporting person, with transaction date 08/12/2025.
- None.
Insights
TL;DR: Officer purchased a modest block of shares; the immediate market impact is likely limited.
The Form 4 documents a purchase of 2,000 shares at $4.81, raising direct holdings to 29,657 shares. For a public company, this size of purchase by a named officer is a straightforward insider acquisition disclosure. There are no derivative transactions or disposals reported. Based solely on the filing, the transaction appears routine and not material to company capital structure.
TL;DR: Disclosure appears complete and timely for a single reporting officer.
The Form 4 names the reporting person, relationship (CFO), transaction date (08/12/2025), transaction code (P), number of shares acquired (2,000) and resulting direct ownership (29,657). The form indicates a single filer and shows no amendments. From a compliance perspective, the filing meets standard Section 16 disclosure elements contained in the document.
David O'Toole, identificato come Chief Financial Officer, ha depositato un Form 4 che segnala una variazione della titolarit脿 effettiva di Avita Medical, Inc. (RCEL). Il documento indica l'acquisto di 2,000 azioni ordinarie in data 08/12/2025 al prezzo di $4.81 per azione, portando la sua partecipazione diretta a 29,657 azioni. L'operazione 猫 segnalata con il codice di transazione P e il Form 4 猫 stato presentato da una sola persona dichiarante.
David O'Toole, identificado como Chief Financial Officer, present贸 un Form 4 informando un cambio en la titularidad de Avita Medical, Inc. (RCEL). El informe muestra que adquiri贸 2,000 acciones ordinarias el 08/12/2025 a un precio de $4.81 por acci贸n, incrementando su tenencia directa a 29,657 acciones. La transacci贸n se reporta con el c贸digo P y el Form 4 fue presentado por una sola persona informante.
David O'Toole鞚� 斓滉碃鞛毂呾瀯鞛�(CFO)搿� 頇曥澑霅橂┌, Avita Medical, Inc. (RCEL)鞐� 雽�頃� 鞁れ 靻岇湢甓� 氤�霃欖潉 氤搓碃頃橂姅 Form 4毳� 鞝滌稖頄堨姷雼堧嫟. 靹滊鞐� 霐半ゴ氅� 攴鸽姅 08/12/2025鞐� 氤错喌欤� 2,000欤茧ゼ 欤茧嫻 $4.81鞐� 旆摑頃橃棳 攴胳潣 歆侅为 氤挫湢霟夓澊 29,657欤茧 歃濌皜頄堨姷雼堧嫟. 瓯半灅電� 瓯半灅 旖旊摐 P搿� 氤搓碃霅橃棃瓿�, Form 4電� 頃� 氇呾潣 氤搓碃鞚胳澊 鞝滌稖頄堨姷雼堧嫟.
David O'Toole, identifi茅 comme Chief Financial Officer, a d茅pos茅 un Form 4 signalant un changement de d茅tention b茅n茅ficiaire de Avita Medical, Inc. (RCEL). Le d茅p么t indique qu'il a acquis 2,000 actions ordinaires le 08/12/2025 au prix de $4.81 par action, portant sa d茅tention directe 脿 29,657 actions. La transaction est d茅clar茅e sous le code P et le Form 4 a 茅t茅 d茅pos茅 par une seule personne d茅clarante.
David O'Toole, ausgewiesen als Chief Financial Officer, hat ein Form 4 eingereicht, das eine 脛nderung des wirtschaftlichen Eigentums an Avita Medical, Inc. (RCEL) meldet. Dem Eintrag zufolge erwarb er am 08/12/2025 2,000 Stammaktien zu je $4.81, wodurch seine direkten Best盲nde auf 29,657 Aktien stiegen. Die Transaktion ist mit dem Transaktionscode P gemeldet, und das Form 4 wurde von einer meldenden Person eingereicht.
FAQ
Who filed the Form 4 for Avita Medical (RCEL)?
What transaction is reported in the RCEL Form 4 dated 08/12/2025?
How many Avita Medical (RCEL) shares does David O'Toole own after the reported transaction?
Was the Form 4 filed jointly or by a single reporting person?
Does the filing report any derivative securities or option transactions?
